SCHEMBL6316767

SCHEMBL6316767

Nc1onc(-c2cccs2)c1C(=O)NCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.61
NPC1 O15118 5/20 0.61
NPSR1 Q6W5P4 1/20 0.61
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
HPGDS O60760 1/20 0.51
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
ALDH1A1 P00352 2/20 0.49
PLEC Q15149 1/20 0.49
GAA P10253 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA1 P30542 1/20 0.48
TP53 P04637 1/20 0.47
HDAC1 Q13547 1/20 0.47
ESR1 P03372 1/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.45
KDM4E B2RXH2 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315911 0.90 KMT2A (0.63) RAB9ANPC1NPSR1LMNASMN1; SMN2
SCHEMBL6318330 0.83 CA1 (0.56) RAB9ALMNASMN1; SMN2KMT2AMEN1
SCHEMBL6317603 0.83 GAA (0.53) RAB9ANPC1NPSR1SMN1; SMN2KMT2A
SCHEMBL6315227 0.82 HPGD (0.56) RAB9ANPC1NPSR1SMN1; SMN2KMT2A
SCHEMBL6324462 0.82 GAA (0.46) RAB9ANPC1NPSR1LMNASMN1; SMN2
SCHEMBL6316706 0.82 GAA (0.46) RAB9ANPC1NPSR1LMNASMN1; SMN2
SCHEMBL6316598 0.82 CA1 (0.56) RAB9ANPC1NPSR1KMT2AMEN1
SCHEMBL6316604 0.81 ALDH1A1 (0.57) SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL6318418 0.81 POLB (0.53) RAB9ANPC1NPSR1LMNASMN1; SMN2
SCHEMBL6317805 0.81 GAA (0.48) RAB9ANPC1NPSR1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885NPC1 3741/4885NPSR1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.